Short description
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Description
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death (a.k.a. apoptosis - ἁπόπτωσισ is used in Greek to describe the "falling off" of leaves from trees) or on the inhibition of tumour cell growth. The lead product candidate of the company, APG101, is currently in a controlled phase II proof of concept study with GBM patients (GBM: Glioblastoma multiforme).
Last funding
No Way
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Heidelberg, Baden-Wurttemberg, Germany, Europe
Founded on
January 1, 2005
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccessforu, No Way
Sign in for full access
Founders
Peter Krammer